Medical technology company Teleflex (NYSE:TFX) in Q4 CY2025, with sales falling 28.5% year on year to $569 million. Its non-GAAP profit of $1.93 per share was 48.4% below analysts’ consensus estimates.

Teleflex Incorporated (NYSE: TFX) (the "Company") today announced financial results for the year ended December 31, 2025.

Q4 2025 earnings call recap: divestitures, $1.8B proceeds, $1B buyback, 2026 EPS $6.25–$6.55, risks & outlook—read now.

Investing.com - Teleflex (NYSE: TFX) reported fourth quarter EPS of $1.93, $1.86 worse than the analyst estimate of $3.79. Revenue for the quarter came in at $568.98M versus the consensus estimate of $925.44M.

WAYNE, Pa., June 28, 2021 (GLOBE NEWSWIRE) -- Today, Teleflex Incorporated (NYSE:TFX), a leading global provider for healthcare supplies and services, announced it has completed the previously announced divestiture of a significant portion of its ...

Teleflex has struck a $260 million deal to buy IWG High Performance Conductors as it looks to build on a financial year in which it beat expectations. In fourth quarter results posted Thursday, Teleflex revealed the purchase to gain a portfolio of fine ...

Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its fourth quarter 2025 financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, February 26,

Acquisition will further advance Teleflex’s Interventional portfolio with a differentiated global suite of coronary vascular and peripheral vascular intervention devices WAYNE, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a ...

Investing.com -- Shares of Teleflex (NYSE:TFX) fell 8.8% to $102 in premarket trading on Thursday after the medical device maker reported fourth quarter results that missed Wall Street expectations.